Package Leaflet: Information for the Patient
Omeprazole Hikma 40 mg Powder for Solution for Infusion EFG
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack and other information:
Omeprazole Hikma contains the active substance omeprazole. It belongs to a group of medicines called “proton pump inhibitors”. These medicines work by reducing the amount of acid produced by the stomach.
Omeprazole Hikma powder for solution for infusion can be used as an alternative to oral treatment.
Omeprazole Hikma must not be given to you:
Do not use this medicine if any of the above applies to you. If you are not sure, talk to your doctor, pharmacist, or nurse before you are given this medicine.
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you are given omeprazole. This medicine may hide the symptoms of other diseases. Therefore, if you experience any of the following before you start using this medicine or after you have been given it, tell your doctor immediately:
When taking omeprazole, kidney inflammation may occur. The signs and symptoms may include decreased urine volume or blood in the urine and/or hypersensitivity reactions such as fever, rash, and joint stiffness. You should report such signs to your doctor.
Taking a proton pump inhibitor like omeprazole, especially for more than one year, may slightly increase your risk of fracture in the hip, wrist, or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).
If you get a skin rash, especially in areas of the skin exposed to the sun, you should contact your doctor as soon as possible, as it may be necessary to stop treatment with this medicine. Remember to mention any other symptoms that you may notice, such as joint pain.
Children and adolescents
There is limited experience with this medicine for intravenous use in children.
Other medicines and Omeprazole Hikma
Tell your doctor, pharmacist, or nurse if you are using or have recently used other medicines, including those obtained without a prescription. Omeprazole may affect the way some medicines work and some medicines may affect the way omeprazole works.
You must not be given this medicine if you are taking a medicine that contains nelfinavir (used to treat HIV infection).
Tell your doctor, pharmacist, or nurse if you are taking any of the following medicines:
If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as omeprazole to treat ulcers caused by Helicobacter pylori infection, it is very important that you inform them of any other medicines you are taking.
Talk to your doctor before taking omeprazole if you have ever had a skin reaction after treatment with a medicine similar to this medicine that reduces stomach acid.
Pregnancy and breastfeeding
Before using omeprazole, tell your doctor if you are pregnant or trying to become pregnant. Your doctor will decide whether you can use omeprazole during this time.
Omeprazole is excreted in breast milk, but it is unlikely to affect the baby when used at therapeutic doses. Your doctor will decide whether you can take omeprazole if you are breastfeeding.
Driving and using machines
Omeprazole is unlikely to affect your ability to drive or use tools or machines. However, side effects such as dizziness and visual disturbances (see section 4) may occur. If this happens, do not drive or use machines.
Omeprazole Hikma contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per dose unit, which is essentially "sodium-free".
Administration of omeprazole
If you are given too much Omeprazol Hikma
If you think you have been given too much omeprazole, tell your doctor immediately.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you notice any of the following serious side effects, stop taking this medicine and contact your doctor immediately:
Other side effects are:
Common side effects(may affect up to 1 in 10 people)
Uncommon side effects(may affect up to 1 in 100 people)
Rare side effects(may affect up to 1 in 1,000 people)
Very rare side effects(may affect up to 1 in 10,000 people)
Frequency not known (cannot be estimated from the available data)
Irreversible visual impairment has been reported in isolated cases of critically ill patients treated with omeprazole intravenously, especially at high doses, but a causal relationship has not been established.
In very rare cases, omeprazole may affect the white blood cells in the blood and cause immunodeficiency. If you have an infection with symptoms such as fever with a severely deteriorated general condition or fever with symptoms of local infection, such as sore throat, or difficulty urinating, you should contact your doctor as soon as possible to have a blood test and rule out a lack of white blood cells (agranulocytosis). It is important that you provide information about the medicine you are taking at that time.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vial and carton after "EXP". The expiry date is the last day of the month stated.
Do not store above 25°C.
Store the vial in the outer packaging to protect it from light.
Shelf-life after reconstitution:
The reconstituted solution for infusion with 9 mg/ml of sodium chloride (0.9%) should be used within 12 hours of preparation.
The reconstituted solution for infusion with 50 mg/ml of glucose (5%) should be used within 6 hours of preparation.
From a microbiological point of view, the product should be used immediately, unless it has been reconstituted in controlled and validated aseptic conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Omeprazole Hikma
Appearance and packaging of the product
Omeprazole Hikma 40 mg Powder for Solution for Infusion (powder for infusion) is presented in a vial.
The dry powder in the vial must be incorporated into a solution before administration.
Package sizes: 1 vial x 40 mg and 10 vials x 40 mg.
Not all pack sizes may be marketed.
Marketing authorisation holder:
Hikma Farmacêutica (Portugal) S.A.
Estrada do Rio da Mó, nº8, 8A e 8B, Fervença
2705-906 Terrugem SNT
Portugal
Manufacturer:
Hikma Italia S.p.a
Viale Certosa, 10
27100 - Pavia
Italy
You can obtain further information about this medicine from the local representative of the marketing authorisation holder:
Hikma España, S.L.U.
Calle Anabel Segura nº11, Edificio A, planta 1ª, oficina 2
28108 - Alcobendas, Madrid
Spain
This medicine is authorised in the Member States of the European Economic Area under the following names:
Spain | Omeprazol Hikma 40 mg Polvo para solución para perfusión EFG |
Italy | Omeprazolo Hikma |
Portugal | Omeprazol Hikma |
United Kingdom | Omeprazole 40 mg Powder for Solution for infusion |
Date of last revision of this leaflet: April 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
The entire contents of each vial should be dissolved in approximately 5 ml and then immediately diluted to 100 ml. A solution for infusion of 9 mg/ml of sodium chloride (0.9%) or a solution for infusion of 50 mg/ml of glucose (5%) should be used. The reconstituted solution is not significantly less clear than an equal volume of the diluent contained in a similar container and was examined for similarity. The reconstituted solution should not be used if particles are present. The pH of the solution for infusion affects the stability of omeprazole, which should not be diluted in other solvents or in other quantities for this reason.
Preparation
Alternative method of preparation of infusions in flexible containers
The solution for infusion should be administered as an intravenous infusion over 20-30 minutes. Use in a single treatment for one patient.